Title of Abstract Goes Here – Please Make Sure
Study Number is Listed in Title
Author’s Names
Author’s Affiliations
ABSTRACT
OBJECTIVES
Poster development instructions:
Be sure to check the poster
specifications for each meeting as these
often vary from meeting to meeting. You
should know the poster size prior to
starting to layout your poster.
The components included in this
template are not necessarily required
(such as “Abstract”) and those not
required can be deleted.
• Bullet Number One – sample text sample text
sample text sample text sample sample text sample
text sample text sample text sample text sample text
sample text sample text sample text sample text
sample text.
• Bullet Number Two – sample text sample text
sample text sample text sample sample text sample
text sample text sample text sample text sample text
sample text sample text sample text sample text
sample text.
RESULTS
PATIENTS
• Bullet Number One – sample text.
• Bullet Number Two – sample text
sample text.
Table I. Patient Accrual
Background: Patients with tumors Patients with
tumors Patients with tumors Patients with tumors
Patients with tumors Patients with tumors Patients
with tumors Patients with tumors Patients with tumors
Patients with tumors.
Be sure to check the poster specifications for each
meeting as these often vary from meeting to meeting.
You should know the poster size prior to starting to
layout your poster. The components included in this
template are not necessarily required and those not
required can
Methods: Patients with tumors Patients with tumors
Patients with tumors Patients with tumors Patients
with tumors Patients with tumors Patients with tumors
Patients with tumors Patients with tumors Patients
with tumors.
Results: 106 patients were enrolled 106 patients were
enrolled 106 patients were enrolled 106 patients were
enrolled 106 patients were enrolled 106 patients were
enrolled 106 patients were enrolled 106
sample text sample text sample text 100
• Bullet Number One – sample text sample text
sample text sample text sample sample text sample
text sample text sample text sample text sample text
sample text sample text sample text sample text
sample text.
• Bullet Number Two – sample text sample text
sample text sample text sample sample text sample
text sample text sample text sample text sample text
sample text sample text sample text sample text
sample text.
• Bullet Number Three – sample text sample text
sample text sample text sample sample text sample
text sample text sample text sample text sample text
sample text sample text sample text sample text
sample text
STUDY DESIGN
sample text sample text sample text 100
sample text sample text sample text 100
Table II. Pretreatment
sample text sample text sample text 100
sample text sample text sample text 100
sample text sample text sample text 100
Study design goes here.
sample text sample text sample text 100
sample text sample text sample text 100
Conclusion: Both regimens were well tolerated with
acceptable Both regimens were well tolerated with
acceptable Both regimens were well tolerated with
acceptable tolerated with acceptable Both regimens
were
Table VII. Overall
sample text sample text sample text 100
sample text sample text sample text
100
sample text sample text sample text 100
sample text sample text sample text
100
sample text sample text sample text 100
sample text sample text sample text
100
SAFETY AND TOXICITY
ELIGIBILITY
Size: 42 x 42
Table IV. Patient Accrual
Table V. Pretreatment
sample text sample text sample text
100
Sample text sample text sample text 100
sample text sample text sample text
100
sample text sample text sample text
100
sample text sample text sample text
100
sample text sample text sample text
100
sample text sample text sample text
100
sample text sample text sample text
100
sample text sample text sample text
100
sample text sample text sample text
100
sample text sample text sample text
100
Table VIII. Causes of Death
sample text sample text sample text
100
sample text sample text sample text
100
sample text sample text sample text
100
CONCLUSIONS
• Sample text Sample text Sample text
Sample text Sample text Sample text
Sample text Sample text Sample text
Sample text
• Sample text Sample text Sample text
Sample text Sample text
• Sample text Sample text Sample text
Sample text Sample text
• Sample text Sample text Sample text
Sample text Sample text
EFFICACY
BACKGROUND
Figure 1: Treatment Schema
Table III. Pathologic Response
Table VI. Toxicities
Aim 1
• Bullet Number One – sample text sample text
sample text sample text sample sample text sample
text sample text sample text sample text sample text
sample text sample text sample text sample text
sample text sample text sample text sample text
sample text sample text sample text sample text text
sample text.
• Bullet Number Two – sample text sample text
sample text sample text sample sample text sample
text sample text sample text sample text sample text
sample text sample text sample text sample text
sample text sample text sample text sample text
sample text sample text sample text sample text text
sample text.
• Bullet Number Three – sample text sample text
sample text sample text sample sample text sample
text sample text sample text sample text sample text
sample text sample text sample text sample text
sample text sample text sample text sample text
sample text sample text sample text sample text text
sample text.
Number One – sample text sample text sample
text sample text sample sample text sample text
Number Two – sample text sample text sample
text sample text sample sample text sample text.
1.
sample text sample text sample text 100
sample text sample text sample text
2.
sample text sample text sample text
100
sample text sample text sample text 100
sample text sample text sample text 100
Aim 2
Number Two – sample text sample text sample
text sample text sample sample text sample text.
100
sample text sample text sample text 100
sample text sample text sample text
Number One – sample text sample text sample
text sample text sample sample text sample text
REFERENCES
100
3.
4.
sample text sample text sample text 100
5.
sample text sample text sample text 100
6.
7.
8.
Sample text sample text sample text sample text sample
text sample text sample text sample text sample text
sample text.
Sample text sample text sample text sample text sample
text sample text sample text sample text sample text
sample text
Sample text sample text sample text sample text sample
text sample text sample text sample text sample text
sample text
Sample text sample text sample text sample text sample
text sample text sample text sample text sample text
sample text
Sample text sample text sample text sample text sample
text sample text sample text sample text sample text
sample text
Sample text sample text sample text sample text sample
text sample text sample text sample text sample text
sample text
Sample text sample text sample text sample text sample
text sample text sample text sample text sample text
sample text
Sample text sample text sample text sample text sample
text sample text sample text sample text sample text
sample text
Sponsor acknowledgements
NCT number